Immunotherapy for Leukemia

What is Leukemia?

A type of cancer that can affect the bone marrow, causing it to produce too many immature white blood cells. Leukemia is classified as either chronic or acute, depending on how quickly the abnormal cells are dividing.

Acute leukemia is most often found in children and teens. Chronic leukemia usually starts in adults older than 55.

There are two main types of leukemia: Acute Lymphoblastic Leukemia (ALL) and Acute Myelogenous Leukemia (AML).

Leukemia is a type of cancer that affects the bone marrow, causing it to produce too many immature white blood cells. The two main types of leukemia are acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML).

 

 

 

How Immunotherapy Works for Leukemia

Immunotherapy, also known as biological therapy, stimulates the immune system to fight cancer cells. It generally produces fewer short-term side measure than chemotherapy.

Research on blood cancer is ongoing with the use of immunotherapies, including:

Doctors use immunotherapy in a few ways to correct a blood cancer. This includes

  • In certain types of cancers, FDA-approved drugs can be combined with other treatment methods to maximize chances of success.
  • Combination chemotherapy is a powerful treatment that has proven to be successful in many cases. Nonetheless, you may choose maintenance therapy in order to maintain a good quality of life and prevent recurrence.
  • As a single agent 

 

Cancer and the Immune System

Most people know that the immune system protects your body from infections and diseases. It includes a network of cells and organs which provide protection from antigens. These antigen include bacteria, viruses, fungi, toxins & allergens.When antigens are ingested or come into contact with the skin or mucous membranes, they stimulate an immune response: White cells produce antibodies that coat the antigens which helps to identify them as targets. This helps the body know how to react to them by getting more white cells involved or inactivating them.

Most of the time, your natural immune system fails to identify cancer cells as invaders. One reason for this may be that cancer cells aren’t external invaders like viruses and bacteria are. Instead, cancer cells are altered versions (mutations) of normal cells and don’t produce a unique feature like an antigen that will trigger an immune response.

Immunotherapy is based on the idea that immune cells or antibodies can be produced in a lab to recognize cancer cells and get rid of them. These are then given to patients to treat cancer. There are a number of different types of immunotherapy currently approved or under clinical trials for a variety of cancers.

 

Immunotherapy Treatment Approaches

Scientists research the ways of administering immunotherapy and focus on three strategies:

  • To rid the body of cancer cells, immune cells are taken from either the patient or a transplant donor. These immune cells are used to attack any residual leukemia, lymphoma, or myeloma (HTM) cancer cells that may remain after chemotherapy.
  • Synthetic antibodies can attach to antigens on the cancer cells, using samples of tumors.
  • The use of vaccines to suppress cancer cells left behind after treatment and prolong remission is an emerging field.

Types of Immunotherapies

 

Chimeric antigen receptor (CAR) T-cell therapy

This is an immunotherapy technique. The cells are removed from the patient during apheresis and modified in a lab so they target tumor cells through the use of a gene modification technique. Once they are edited, they are returned to the patient before being put back inside them.

Cytokine Treatment

Other treatments used to stimulate the immune system in a general way and combined with methods such as monoclonal antibodies, vaccines or chemotherapy are substances called cytokines—hormones produced by the body that help the immune system function. Cytokines that are artificially produced can be used as an adjunct to stimulate the immune system. Examples of these treatments are:

  • Granulocyte-macrophage colony-stimulating factor (GM-CSF)

  • Interleukin-2 (IL-2)

  • Interferon

Donor lymphocyte infusion

Some patients with chronic leukemia, especially those who have a relapse after stem cell transplantation or who are not accepted for that therapy, may benefit from an immune cell treatment called donor lymphocyte infusion.

During this procedure, doctors transfer white blood cells called lymphocytes from the original stem cell donor’s blood into the patient. The infusion usually helps produce an immune reaction that targets leukemia cells and can ultimately eliminate them, preventing further complications. This is called a GVT effect.

Lymphocyte infusion has been useful in treating patients with chronic myeloma who have relapsed after an allograft.

Monoclonal Antibody Treatment

Monoclonal antibody therapy can sometimes be referred to as passive immunotherapy because it does not directly stimulate your immune system to respond to diseases. Instead, monoclonal antibody therapy mimics the natural antibodies made by the body.

Monoclonal antibodies are made in the lab and designed to react with or attach to antigens on cancer cells. This helps them identify and destroy them as well as reduce inflammation. Monoclonal antibodies target your cells, attaching themselves to it and stopping the cell from functioning. The antibody also recognizes a specific marker on the cell (marker=target). That’s why this part of cancer treatment is called targeted therapy.

Monoclonal antibody therapies can contribute to various side effects, but they’re typically less severe than chemotherapy. Given they provide the opportunity to target and attack specific substances, they ordinarily leave normal cells unharmed.

Doctors can use monoclonal antibodies either on their own or attached to other substances:

  • Naked antibodies don’t have another chemical or radioactive material attached. Rituximab (Rituxan®) and alemtuzumab (Campath®) are examples of naked monoclonal antibody therapy. When antibodies come in contact with the target cell, they are able to destroy it. They do this because they are specifically designed to attach securely to the cell’s receptor site.

  • Conjugated antibodies have radioactive isotopes (radioimmunotherapy) or toxins (immunotoxin) attached to them. Daunorubicin (Cerubidine®), doxorubicin (Adriamycin®), idarubicin (Idamycin®) and mitoxantrone (Novantrone®) are examples of conjugated antibody therapy. Phrases like these destroy cancer cells and the toxic substances they contain.

What to Expect

Monoclonal antibody therapies are typically given in outpatient settings, over the course of several weeks. The drug is delivered through a needle placed into your vein (intravenous infusion). Your doctor may give drugs before and after IV treatment to prevent certain side effects. They regularly test your blood during & after treatment.

The most common side effects of Rituxan and Campath are fever, chills, tiredness, headache and nausea. Rare side effects of Omnipod include shortness of breath, a drop in blood pressure, an irregular heartbeat, chest pain and low blood cell counts.

Radioimmunotherapy

Radioimmunotherapy is mainly used to treat lymphoma and lymphocytic leukemia by combining a radioactive substance with a monoclonal antibody that’s injected into your body. Monoclonal antibodies can bind to antigens on cancer cells, sometimes causing reactions. The radioactive molecules then destroy the cells.

Monoclonal antibodies are laboratory made immune proteins. Ibritumomab is a common monoclonal antibody, used for a blood cancer treatment in a clinical trial.

Radioimmunotherapy is a less toxic treatment option than chemotherapy. It doesn’t cause hair loss, carries a lower risk of nausea and fatigue and it also lowers your red & white blood cell counts. Most people experience a rapid recovery after.

What to Expect

Some patients may experience serious nausea and vomiting when they go for treatment. But before you can get started, your medical practitioner will prescribe anti-nausea drugs to combat these symptoms. The medical practitioner will also give you iodide pills before administering radioactive iodine-linked antibodies.

In most cases Zevalin is administered at a hospital as an outpatient procedure, although it can be done in a patient’s home. The course of treatment lasts around 2 weeks and is started with a few days of intravenous therapy, which will prepare the body to receive the actual radioactive material. It is recommended to get the treatment on the same day, every time. Usually, the patient will receive an infusion of antibodies. Then, 4 hours after getting the antibody infusion, they will get a dose of radiation. The injection takes about 10 minutes to administer.

Infusion reactions are a major concern for those who use blood thinner medications. Speak with your doctor if you develop these symptoms, as they can occur both during and after treatment. In some cases, drugs may be prescribed to help ease or prevent these side effects.

After Treatment

When you finish treatment, you’ll need routine blood work for the following few months in order to check that your full blood cell count has recovered. Most patients experience a moderate decrease in blood cell production for a short period of time. If you had chemotherapy or external radiotherapy before radioimmunotherapy, you may have a greater degree of cytopenia (low blood counts).

Some patients will have mild to moderate reactions that won’t be too major. These include:

  • Low blood pressure

  • Diarrhea

  • Rash or swelling at the injection site

You must take certain precautions to protect the people around you from radiation exposure. Your doctor and nurse will explain the precautions, which are very easy to follow and won’t restrict your quality of life.

Radioimmunotherapy can take months to work. Your doctor monitors it with checkup visits and imaging tests like CT scans & the production of radioactive substances (positron emission tomography). Radioimmunotherapy is usually well tolerated.

Clinical Trials

Interested in immunotherapy? Speak to your physician and find out whether it’s right for you. If we’re not able to offer it, you may be eligible for a clinical trial that studies a type of immunotherapy. Feel free to contact us at 734-404-6065 if you have any questions.